According to @CNBC, Novo Nordisk (NVO) shares plunged to a four-year low after the company's Alzheimer's disease drug trial failed to hit a key primary target. CNBC linked the selloff directly to the trial miss in its coverage. CNBC did not mention any direct impact on cryptocurrencies in this update.

According to @ReutersBiz, Brazil’s Ambipar obtained court protection in a debt dispute and its shares dived on the news; the report did not indicate any direct cryptocurrency market impact. Source: @ReutersBiz